Osteoboost Joins AgeTech Collaborative™ from AARP Accelerator Program

One of the biggest challenges of aging is the loss of bone density, which too often leads to osteoporosis and serious fractures that significantly impact quality of life. 

Our mission with Osteoboost is to slow the process of bone loss and preserve bone density and strength, helping people live stronger, more active lives longer. To deliver on this promise, industry collaboration is key. 

Today we are happy to announce that Osteoboost has been accepted into the AgeTech Collaborative™ from AARP® accelerator, an 8-week program designed to elevate promising early-stage AgeTech startups.

AgeTech Collaborative from AARP is an unparalleled innovation ecosystem bringing together cutting-edge thinkers in the longevity tech space to champion meaningful advances so that everyone can choose how they live as they age.

The soon-to-launch Osteoboost wearable precision vibration therapy device is an ideal fit with this program. As the first FDA-cleared drug-free prescription treatment for osteopenia in postmenopausal women, Osteoboost offers a novel approach to the age-old problem of low bone density affecting millions of people worldwide, an area that has been starved for innovation

With preorders for the Osteoboost Founder’s Program opening soon (register here for launch notifications!) and the first devices poised to ship in the coming months, the support from the AgeTech Collaborative™ from AARP will be invaluable to helping raise both industry and patient awareness. The opportunity will give us access to an incredible network of innovators and resources that will accelerate our ability to  provide patients with access to Osteoboost.

The future of bone health is brighter than ever, and we are thrilled to join this exciting ecosystem as we move closer to public availability.